Drug Profile


Alternative Names: IL-8; Interleukin-8

Latest Information Update: 26 Jun 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antibacterials; Antineoplastics
  • Mechanism of Action Cytokine stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections; Cancer

Most Recent Events

  • 21 Jun 2001 No-Development-Reported for Cancer in Austria (Unknown route)
  • 01 Apr 1996 Interleukin-8 is now called emoctakin
  • 01 Sep 1995 Three studies have been added to the pharmacodynamics section ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top